Description

α-Conotoxin TxID is a potent α3β4 nAChR antagonist with an IC50 value of 12.5 nM. α-Conotoxin TxID has weak inhibition activity of closely related α6/α3β4 nAChR (IC50= 94 nM). α-Conotoxin TxID has the potential for novel smoking cessation drug development[1].—–C58H92N18O18S5—-[1]Xiaodan Li, et al. α-Conotoxin TxID and [S9K]TxID, α3β4 nAChR Antagonists, Attenuate Expression and Reinstatement of Nicotine-Induced Conditioned Place Preference in Mice. . Mar Drugs. 2020 Dec 16;18(12):646. doi: 10.3390/md18120646.–1496617-64-1–1489.79—-O=C([C@@H](NC([C@@H](NC([C@@](CSSC[C@H](NC([C@](NC([C@@](CCC1)([H])N1C2=O)=O)([H])[C@@H](C)CC)=O)C(N)=O)([H])NC3=O)=O)CO)=O)CC4=CN=CN4)N(CCC5)[C@]5([H])C(N[C@H](C(N[C@](CSSC[C@@H]3NC(CN)=O)([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]2CO)=O)CCSC)=O)C)=O)CO)=O)=O)C(C)C)=O–Neurological Disease–10 mM in DMSO–nAChR—-Membrane Transporter/Ion Channel;Neuronal Signaling–Peptides